Amarin Hit With Stock Drop Suit Over Drug Trial Results
Amarin Corp. has been hit with a putative class action alleging it made false statements about clinical trial results for cardiovascular drug Vascepa, leading its stock price to drop by nearly...To view the full article, register now.
Already a subscriber? Click here to view full article